Literature DB >> 8763848

Tirapazamine: hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay.

T Shibata1, Y Shibamoto, K Sasai, N Oya, R Murata, T Takagi, M Hiraoka, M Takahashi, M Abe.   

Abstract

We investigated the cytotoxicity and the interaction with low-dose radiation (1-4Gy) of tirapazamine by the in vitro cytokinesis-block micronucleus (MN) assay. Murine SCCVII and human melanoma (G-361) cells were treated with tirapazamine under aerobic or hypoxic conditions for 1 h and the MN frequency was determined using cytochalasin-B. The cells were also treated with or without tirapazamine or KU-2285 (hypoxic cell sensitiser) under hypoxic conditions and irradiated with or without reaeration of the cell suspensions. A dose-dependent increase of MN frequency was observed by tirapazamine treatment and the hypoxic toxicity ratio was about 130 for SCCVII and 37 for G-361. The radiation dose-response curves of MN frequency suggested that the interaction of tirapazamine with irradiation appeared to be essentially additive in both cell lines. In contrast, the dose-response curve became steeper by KU-2285 treatment. Combined effects of tirapazamine and irradiation on the hypoxic cells were much higher than the radiation effect on aerobic cells at low doses, while the effects of KU-2285 did not exceed that of aerobic irradiation. In conclusion, tirapazamine appeared to be superior to hypoxic radiosensitisers at clinically relevant doses, not because of aerobic radiosensitisation but because of its potent hypoxic cytotoxicity additive to radiation effect.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8763848      PMCID: PMC2149998     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  21 in total

1.  Comparison of radiosensitizing effect of KU-2285 and SR-2508 at low drug concentrations and doses.

Authors:  T Shibata; Y Shibamoto; N Oya; K Sasai; R Murata; T Ishigaki; M Abe
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-06-15       Impact factor: 7.038

2.  SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells.

Authors:  E M Zeman; J M Brown; M J Lemmon; V K Hirst; W W Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-07       Impact factor: 7.038

3.  Vasoactivity, a potentially important variable in the sequencing of tirapazamine (SR 4233) and radiation.

Authors:  S Senan
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-01-01       Impact factor: 7.038

4.  Assessment of micronucleus induction in SCCVII cells treated with bioreductive agents, WIN 59075 (SR 4233) and mitomycin C, under aerobic and hypoxic conditions.

Authors:  T Shibata; Y Shibamoto; K Sasai; N Oya; T Takagi; R Murata; M Abe
Journal:  Mutat Res       Date:  1995-04       Impact factor: 2.433

Review 5.  Tumour hypoxia: the picture has changed in the 1990s.

Authors:  J M Brown; A J Giaccia
Journal:  Int J Radiat Biol       Date:  1994-01       Impact factor: 2.694

6.  Reoxygenation and rehypoxiation in the SCCVII mouse tumor.

Authors:  I H Kim; J M Brown
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-06-15       Impact factor: 7.038

Review 7.  Sensitizers and radiation dose fractionation: results and interpretations.

Authors:  R P Hill
Journal:  Int J Radiat Oncol Biol Phys       Date:  1986-07       Impact factor: 7.038

Review 8.  SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.

Authors:  J M Brown
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

9.  Assessment of the proliferative activity and radiosensitivity of human tumours using the cytokinesis-block micronucleus assay.

Authors:  Y Shibamoto; T Shibata; S Miyatake; Y Oda; T Manabe; G Ohshio; K Yagi; C Streffer; M Takahashi; M Abe
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

10.  Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.

Authors:  D G Hirst; J M Brown; J L Hazlehurst
Journal:  Br J Cancer       Date:  1982-07       Impact factor: 7.640

View more
  2 in total

1.  Applicability of combination with tirapazamine in boron neutron capture therapy.

Authors:  S Masunaga; K Ono; Y Sakurai; H Hori; T Kobayashi; M Takagaki; M Suzuki; Y Kinashi; M Akaboshi
Journal:  Jpn J Cancer Res       Date:  1998-07

Review 2.  G2/M-Phase Checkpoint Adaptation and Micronuclei Formation as Mechanisms That Contribute to Genomic Instability in Human Cells.

Authors:  Danî Kalsbeek; Roy M Golsteyn
Journal:  Int J Mol Sci       Date:  2017-11-06       Impact factor: 5.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.